An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib

Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overco...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Mitsuo, Matsui, Akira, Shimoyama, Yoshie, Omote, Norihito, Morise, Masahiro, Hase, Tetsunari, Tanaka, Ichidai, Suzuki, Kojiro, Hasegawa, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306534/
https://www.ncbi.nlm.nih.gov/pubmed/30101911
http://dx.doi.org/10.2169/internalmedicine.0999-18
_version_ 1783382804319436800
author Sato, Mitsuo
Matsui, Akira
Shimoyama, Yoshie
Omote, Norihito
Morise, Masahiro
Hase, Tetsunari
Tanaka, Ichidai
Suzuki, Kojiro
Hasegawa, Yoshinori
author_facet Sato, Mitsuo
Matsui, Akira
Shimoyama, Yoshie
Omote, Norihito
Morise, Masahiro
Hase, Tetsunari
Tanaka, Ichidai
Suzuki, Kojiro
Hasegawa, Yoshinori
author_sort Sato, Mitsuo
collection PubMed
description Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.
format Online
Article
Text
id pubmed-6306534
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-63065342018-12-27 An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib Sato, Mitsuo Matsui, Akira Shimoyama, Yoshie Omote, Norihito Morise, Masahiro Hase, Tetsunari Tanaka, Ichidai Suzuki, Kojiro Hasegawa, Yoshinori Intern Med Case Report Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation. The Japanese Society of Internal Medicine 2018-08-10 2018-12-01 /pmc/articles/PMC6306534/ /pubmed/30101911 http://dx.doi.org/10.2169/internalmedicine.0999-18 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sato, Mitsuo
Matsui, Akira
Shimoyama, Yoshie
Omote, Norihito
Morise, Masahiro
Hase, Tetsunari
Tanaka, Ichidai
Suzuki, Kojiro
Hasegawa, Yoshinori
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
title An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
title_full An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
title_fullStr An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
title_full_unstemmed An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
title_short An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
title_sort egfr-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306534/
https://www.ncbi.nlm.nih.gov/pubmed/30101911
http://dx.doi.org/10.2169/internalmedicine.0999-18
work_keys_str_mv AT satomitsuo anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT matsuiakira anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT shimoyamayoshie anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT omotenorihito anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT morisemasahiro anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT hasetetsunari anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT tanakaichidai anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT suzukikojiro anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT hasegawayoshinori anegfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT satomitsuo egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT matsuiakira egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT shimoyamayoshie egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT omotenorihito egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT morisemasahiro egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT hasetetsunari egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT tanakaichidai egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT suzukikojiro egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib
AT hasegawayoshinori egfrmutatedlungadenocarcinomaundergoingsquamouscellcarcinomatransformationexhibitedadurableresponsetoafatinib

Ejemplares similares